September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Eplerenone in the treatment of active central serous chorioretinopathy.
Author Affiliations & Notes
  • Oussama Boundaoui
    RETINA, RETINA INSTITUTE OF CALIFORNIA, San Gabriel, California, United States
  • Andrew Chon
    RETINA, RETINA INSTITUTE OF CALIFORNIA, San Gabriel, California, United States
  • Michael Davis
    RETINA, RETINA INSTITUTE OF CALIFORNIA, San Gabriel, California, United States
  • Footnotes
    Commercial Relationships   Oussama Boundaoui, None; Andrew Chon, None; Michael Davis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1111. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Oussama Boundaoui, Andrew Chon, Michael Davis; Eplerenone in the treatment of active central serous chorioretinopathy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1111.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Central serous chorioretinopathy (CSCR) is an idiopathic condition featuring serous detachments of the neuosensory retina and/or retinal pigment epithelium (RPE) caused by avascular fluid exudation through the RPE. We evaluated the efficacy of systemic eplerenone, a mineralocorticoid receptor anatagonist, in the treatment of CSCR by examining its effect on central foveal thickness and visual acuity.

Methods : Retrospective case series of 11 patients (9 male, 2 female) with active central serous chorioretinopathy. All patients underwent a fundoscopic examination and spectral-domain optical coherence tomography. Exclusion criteria included concurrent therapy for CSCR with topical, focal laser, or systemic therapy. All patients received either 25mg, 50mg, or 100mg of eplerenone daily for at least 1 month. Follow-up ranged from 2 months to 8 months. Nine of eleven patients had chronic CSCR with duration of disease ranging from 4 months to 2 years (mean 9 months). Two of eleven patients had new-onset CSCR, and were treated within 1 month of symptoms due to occupation visual requirements. A two-tailed unpaired t-test was used to compute the statistical significance of pre-treatment and post-treatment variables.

Results : 7 of 11 (63%) patients achieved decrease in central foveal thickness (CFT) after treatment with eplerenone. 3 of 11 patients (27%) achieved complete resolution of subretinal fluid. CFT before eplerenone ranged from 235 to 715 microns (mean 472.18 microns), and after treatment ranged from 128 to 580 microns (mean 329.73 microns). The decrease in CFT after treatment was statistically significant (p=0.034). No statistically significant improvement in visual acuity was found (p=0.8734)

Conclusions : Eplerenone shows efficacy in the treatment of CSCR by reducing the central foveal thickness. Visual acuity, however, did not improve. A large prospective randomized trial is needed to further investigate the role of eplerenone in the treatment of CSCR.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.